BMJ Open

Associations of subclinical heart failure and atrial fibrillation with mild cognitive impairment: a cross-sectional study in a subclinical heart failure screening programme

Elizabeth L Potter, Satish Ramkumar, Leah Wright, Thomas H Marwick

INTRODUCTION

Mild cognitive impairment (MCI) describes objective evidence of cognitive impairment (CI) without significant compromise to independent functioning. It is a prelude to dementia—a major contributor to mortality and morbidity in our ageing population. Heart failure (HF) and atrial fibrillation (AF) increase risk of CI, with between 54% and 74% of HF patients affected. Furthermore, MCI in HF compromises self-management and leads to worse outcomes. Early detection and prevention of HF and AF may consequently serve to reduce the burden of MCI. Trials evaluating screening for subclinical left ventricular (LV) dysfunction (LVD) and AF, should incorporate cognitive assessment, not only to inform future screening and prevention strategies but to elucidate clinical associations and mechanisms.

CI in HF is associated with medial temporal lobe atrophy and lower cerebral grey matter volume on neuroimaging, changes that are more marked compared with those with risk factors but without HF. Whether this is the case in the subclinical phase of HF failure, that is, LVD without HF symptoms, is uncertain. Limited data suggest subclinical LVD is independently associated with MCI. In addition, reduced systolic function assessed by...
global longitudinal strain (GLS) has been associated with silent cerebral infarcts (SCIs), independent of vascular risk factors. 10 Left atrial (LA) enlargement has been linked with MCI but this does not appear independent of AF, particularly in longitudinal analyses. 11 AF may exert its effect on cognitive function via SCIs, presumably due to cardiogenic embolism. The impact of subclinical AF (asymptomatic AF, unrecognised without screening) or LA function on cognition are unknown.

Should screening programmes for subclinical HF and AF be advocated, the cognitive status of the target population must be quantified to inform effective programme design and implementation. Furthermore, the presence of an independent link between subclinical LV and LA dysfunction, subclinical AF and CI remains unclear. Accordingly, assessment of cognitive function was undertaken in participants enrolled in the Victorian Study of Echocardiographic detection of Subclinical Left Ventricular Dysfunction (Vic-ELF) to (a) establish prevalence and profile of MCI in this population and (b) identify associations between MCI and LV function, LA function and subclinical AF.

METHODS

Study population

All subjects were participants in the Vic-ELF trial. Baseline data were used for this cross-sectional substudy. Subjects were recruited from the community via primary care and advertising. Those who were asymptomatic and ≥65 years with hypertension (self-reported, on medication or systolic blood pressure (SBP) ≥140/90 mm Hg), type II diabetes mellitus or obesity (body mass index (BMI) ≥30 kg/m²) were eligible for inclusion. Those with a history or symptoms of HF or ischaemic heart disease (based on existing clinical indication for echocardiography), LV ejection fraction ≤40%, >30 days on anticoagulant or oncological life expectancy <1 year were excluded.

Patient and public involvement

Patients were not involved in study design and no evaluation of patient involvement burden was undertaken. All participants will receive information regarding the impact of the research findings after study conclusion.

Clinical assessment

Comprehensive medical and medication history were taken along with clinical examination. Heart rate, resting averaged blood pressures, BMI, waist and hip circumference and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) were recorded along with a six-minute walk test (6MWT) to assess functional capacity, in accordance with standard procedure. 12 Patient-reported functional capacity was assessed using the Duke Activity Score Index, which has shown good correlation with peak oxygen uptake, and is readily expressed in metabolic equivalents, a metric familiar to most cardiologists. Health-related quality of life, depression and anxiety were evaluated with the EQ-5D-5L, Generalized Anxiety Disorder 7-Item Scale and the Patient Health Questionnaire-9, respectively. Habitual physical activity was measured (n=201) using waist-worn accelerometers (ActiLife, ActiGraph, Pensacola, Florida, USA) for 7 days. Recordings of less than 4 days were excluded, leaving a total of 190 suitable for analysis.

Cognitive assessment

The Montreal cognitive assessment (MoCA) was conducted in accordance with instructions. 13 In brief the MoCA is a short (10–12 min) office-based assessment that evaluates the cognitive domains of executive and visuospatial function; attention, concentration and working memory; short-term memory, language skills and orientation (online supplemental material 1). It is validated in ages 55–85 years and is the preferred screening tool for MCI. 14 MCI is diagnosed by a score of <26/30. Graded severity levels of 18–25, 10–17 and <10, are suggested for mild, moderate and severe CI, respectively; although supportive data are lacking. Therefore, all CI will be referred to as MCI. A deficit in a domain is defined herein as ≥1 point loss in that domain. MoCA result was unknown to the investigator (SR) evaluating subclinical AF and atrial function.

Echocardiography

Resting two-dimensional and Doppler echocardiography was performed with standard equipment (ACUSON SC2000, Siemens Healthcare USA, Mountain View, California, USA) and transducer (4V1c, 1.25–4.5 MHz; 4Z1c, 1.5–3.5 MHz) in accordance with guidelines. 15 A vector-velocity imaging algorithm (Syngo VVI, Siemens Medical Solutions, Siemens Healthcare USA, Mountain View, California, USA) was used for GLS quantification and averaged from apical, 2-chamber, 3-chamber and 4-chamber views. Diastolic function was assessed by measuring mitral inflow peak early diastolic velocity (E), peak late diastolic velocity (A), E/A ratio, septal and lateral mitral annular early diastolic velocities (e’ and e’/e’ ratio. Biplane method of disks (Simpson’s modified rule) was used for LA volume quantification and indexed to body surface area (LAVI). Diastolic dysfunction was diagnosed using current recommendations. 16 LV mass (LVM) was calculated using the two-dimensional linear method and indexed to body surface area. LVH was defined as LVMi (LVM indexed to body surface area) 95 g/m² in women, 115 g/m² in men. Subclinical LVD was defined as presence of GLS≤16%, diastolic dysfunction (DD) or LVH.

LA reservoir strain (LARS) measures passive LA stretch during LA filling and is associated with diastolic dysfunction grade, may improve diastolic assessment and is independently predicts incident HF. 17–19 LARS was assessed by speckle-tracking using a third-party software program (TomTec-Arena (VTTA2), Tomtec, Munich, Germany). Apical four and 2-chamber images were selected with a frame rate of 60–80 frames/s. The endocardial border of the LA was manually traced, and strain analysis performed...
using the LV strain algorithm, with the average of both the 4-chamber and 2-chamber values. The reference point for image analysis was taken at the onset of the QRS complex (R-R gating). Abnormal LARS was defined as <24%.

### AF screening and echocardiographic risk markers for AF

Participants without a history of AF or flutter were asked to provide separate consent (n=293). Screening for subclinical AF was performed using a portable, single-lead ECG device (Remon RM-100; Semacare, Beijing, China) using three finger contact electrodes. Recordings lasted 60s and were undertaken three times per day for 2 weeks (ie, 42 recordings). Instructions were given verbally face-to-face and in written form. Battery failure, device malfunction or problems relating to dexterity were recorded. ECG recordings were exported as PDF files for interpretation, and all were assessed by a physician. The presence of AF was defined as a continuous episode of an irregular rhythm ≥30s with a variable R-R interval and absent P waves.

A stepwise risk stratification tool for AF using GLS, LAVI and LARS has been devised. GLS>14.3% determines low risk; GLS<14.3% and a small proportion had a history of stroke or transient ischemic attack (6%) and alcohol abuse (7%). On average, the group spent 66% of waking time sedentary with levels of moderate-vigorous physical activity (MVPA) falling well below guideline recommendations. Serum NT-proBNP was, on average, in the low-risk range, that is, <125 pg/mL (51 pg/mL (IQR 30–100)).

### Characteristics of CI and relation to LV function

With regards cognitive assessment by MoCA, 101 (30%) exhibited MCI with an overall average MoCA score of 27 (IQR 25–29). Of the 101 participants with MCI, severity staging showed none with severe CI and only 3 with moderate CI thus the majority had MCI corresponding to a MoCA score between 18 and 25. Overall, delayed recall and executive function had the highest proportion of deficits (237 (70%) and 145 (43%), respectively (table 2). There were no differences in the proportion of cognitive domain deficits between those with and without subclinical LVD, except for orientation, although only 2% of participants had deficits in this domain (table 2).

### Subclinical AF screening and CI

Of the 293 screened, there were 10 instances of device malfunction leaving 283 for analysis. Subclinical AF was detected in 11 (3.9%). Subclinical AF was equally incident in those with and without MCI, as was pre-existing AF (table 1). In those with pre-existing AF, only 13 (57%) were taking an anticoagulant. By echocardiographic AF risk stratification, 9 (3%) were deemed high risk and again there was no association with MCI (table 1). MCI was significantly associated with a reduced number of recordings (<30 recordings), 51 (25%) and 33 (40%) for no MCI and MCI, respectively, p=0.01. Therefore, in those undergoing AF screening with a handheld device a 12% (33/283) rate of non-adherence, related to MCI, was observed.

### Clinical and echocardiographic associations with CI

Those with MCI were less obese and reported significantly fewer years of formal education (table 1). There was a non-significant trend towards higher blood pressure and longer duration of a diagnosis of hypertension and type II diabetes. The proportion with at least moderate anxiety or depression did not differ by presence of MCI, and while on average functional capacity by 6MWT and minutes per week of MVPA were less in those with MCI, neither were statistically significant (table 1). Overall, 155 (46%) had subclinical LVD. Echocardiographic markers of systolic and diastolic LV function did not differ by presence of MCI (table 3). However, LVMI was significantly higher in those with MCI compared with normal cognition (75 g/m² (IQR 60–84) vs 67 g/m² (IQR 55–79), p=0.04, respectively), although this did not translate into a greater proportion of those with MCI having LVH (7% vs 13 (5.5%), p=0.62, respectively). LA function measured by LARS was abnormal (<24%) in 9 (3.6%) with a mean value of 36.2%±7%. LARS did not differ by presence of MCI, nor did the proportion of those with abnormal LARS (table 3).
In univariable logistic regression modelling, no echocardiographic markers of LV or LA function, nor presence of AF showed an association with MCI (table 4). Prior cerebrovascular accident, education duration, SBP, BMI and waist-to-hip ratio (WHR) were associated with MCI (p<0.1) (table 4). In multivariable analysis, MCI was independently associated with higher SBP (OR 1.02 (1.00–1.04), p=0.03) and WHR (OR 40 (2.3–708), p=0.01), while greater numbers of years in formal education (0.9 (0.86–0.98), p=0.01) and higher BMI (0.9 (0.85–0.95), p<0.001) were independently associated with normal cognition.

**DISCUSSION**

Up to 30% of individuals included in a screening programme for subclinical LVD and AF had MCI, manifest most commonly as executive dysfunction, and poor

---

**Table 1** Clinical, anthropometric, functional and physical activity measures by presence or absence of mild cognitive impairment (MCI)

| Measure                              | All (n=337) | No MCI (n=236) | MCI (n=101) | P value |
|--------------------------------------|-------------|----------------|-------------|---------|
| Age, years (IQR)                     | 70 (68–73)  | 70 (68–73)     | 70 (67–73)  | 0.83    |
| Gender, female (%)                   | 194 (58)    | 140 (59)       | 54 (64)     | 0.32    |
| Hypertension (%)                     | 292 (87)    | 201 (85)       | 91 (90.1)   | 0.22    |
| Hypertension duration, years (IQR)  | 13 (7–20)   | 12 (7–20)      | 15 (7–20)   | 0.56    |
| Type II diabetes (%)                 | 108 (32)    | 72 (31)        | 36 (36)     | 0.36    |
| Diabetes duration, years (IQR)      | 8 (5–15)    | 7 (4.5–12.5)   | 10 (5–18)   | 0.1     |
| Obesity (%)                          | 214 (64)    | 158 (68)       | 56 (56)     | 0.04    |
| Dyslipidaemia (%)                    | 208 (62)    | 145 (62)       | 63 (62)     | 0.9     |
| Ever smoker (%)                      | 152 (45)    | 110 (47)       | 42 (42)     | 0.34    |
| AF, known (%)                        | 23 (7)      | 14 (6)         | 9 (9)       | 0.32    |
| AF, detected by screening* (%)       | 11 (4)      | 8 (4)          | 3 (4)       | 0.88    |
| High risk for AF† (%)                | 9 (3)       | 8 (3)          | 1 (1)       | 0.21    |
| Stroke/TIA                           | 21 (6)      | 11 (5)         | 10 (10)     | 0.07    |
| Alcohol abuse (%)                    | 25 (7)      | 21 (9)         | 4 (4)       | 0.12    |
| ACE-I/ARB (%)                        | 264 (78)    | 183 (78)       | 81 (80)     | 0.59    |
| Beta blocker (%)                     | 37 (11)     | 22 (9)         | 15 (15)     | 0.14    |
| Statin (%)                           | 179 (53)    | 123 (52)       | 56 (55)     | 0.58    |
| Antiplatelet agent (%)               | 68 (20)     | 43 (18)        | 25 (25)     | 0.17    |
| Anticoagulant (%)                    | 16 (5)      | 10 (4)         | 6 (6)       | 0.5     |
| Education, years (IQR)              | 12 (10–15)  | 12 (10–15)     | 11 (10–14)  | 0.02    |
| PHQ-9>6 (moderate depression)       | 27 (8)      | 20 (8.5)       | 7 (6.9)     | 0.63    |
| GAD-7>6 (moderate anxiety)          | 26 (8)      | 19 (8)         | 7 (6.9)     | 0.72    |
| EQ-5D-L score (IQR)                 | 1 (0–2)     | 1 (0–2)        | 1 (0–2)     | 0.77    |
| Systolic BP, mm Hg (IQR)            | 138 (131–150)| 137 (129–149) | 141 (133–151)| 0.07 |
| Diastolic BP, mm Hg (IQR)           | 83 (78–90)  | 83 (77–89)     | 85 (79–91)  | 0.09    |
| BMI, kg/m² (IQR)                    | 31 (28–35)  | 32 (28–36)     | 30 (27–33)  | 0.002   |
| Waist–hip ratio (SD)                | 0.93 (0.09) | 0.92 (0.09)    | 0.94 (0.09) | 0.07    |
| Duke activity score index (IQR)     | 51.7 (46.7–52.7)| 52 (49.5–52.7)| 50.7 (46–52.7)| 0.39 |
| Six-minute walk test, m (IQR)       | 441 (403–476)| 445 (403–477)| 438 (405–472)| 0.49 |
| MVPA, min/week (IQR)                | 63 (18–144) | 65 (18–135)    | 48 (17–152) | 0.89    |
| Sedentary time, % (SD)              | 66 (10)     | 67 (10)        | 64 (9)      | 0.15    |
| NT-proBNP, pg/mL (IQR)              | 51 (30–100) | 55 (31–101)    | 49 (24–95)  | 0.34    |

*Total screened=293.
†Echocardiographic criteria.

ACE-I/ARB, ACE inhibitor/angiotensin receptor blocker; AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; GAD-7, Generalized Anxiety Disorder 7-Item Scale; MVPA, moderate-vigorous physical activity; NT-proBNP, N-terminal pro-brain natriuretic peptide; PHQ-9, Patient Health Questionnaire-9; TIA, transient ischaemic attack.
recall of recently delivered information. This is more prevalent than in unselected people aged >65 years, among whom the prevalence of MCI is 3%–19%. The higher prevalence in our population supports the notion that MCI can be expected in people at risk of HF and AF. This is consistent with evidence that cardiovascular risk factors compromise executive function, which is especially true for hypertension—even at subclinical levels.

For the first time, associations were sought between sensitive deformation markers of LV and LA function (strain) and none were found, nor did we find evidence that subclinical AF or high AF risk was associated with MCI, although the number of subjects concerned was low. However, consistent with existing data, lower educational achievement, higher SBP and visceral adiposity, but lower BMI were independently associated with MCI (figure 1). If an independent association exists between HF and CI, then our data suggest this is not apparent in the subclinical phase of HF.

### Cognition and cardiac disease

There is contemporary focus on cognitive dysfunction in the setting of cardiac diseases, principally HF and AF. CI, specifically vascular CI shares well documented risk factors with HF and AF. Exposure to hypertension, diabetes, smoking and abdominal obesity in mid-life is associated with an accelerated decline in executive function a decade later. This is coupled with MRI evidence of cerebral vascular damage and atrophy.

#### Table 2  Mild cognitive impairment (MCI) and deficits in individual cognitive domains according to presence or absence of subclinical left ventricular dysfunction (LVD)

|                          | Overall (n=337) | MCI (n=101) | Normal LV function (n=175) | Subclinical LVD (n=162) | P value |
|--------------------------|----------------|-------------|-----------------------------|-------------------------|---------|
| MCI (MoCA<26)            | 101 (30)       | 52 (29.7)   | 49 (30.2)                   | 0.9                     |
| Moderate CI (MoCA <18)   | 3 (3)          | 2 (4)       | 1 (2)                       | 0.7                     |
| Executive and visuospatial (%) | 145 (43)      | 70 (69)    | 75 (43)                     | 70 (43)                 | 0.9     |
| Naming (%)               | 15 (4.5)       | 9 (9)       | 6 (3.4)                     | 9 (5.6)                 | 0.34    |
| Attention (%)            | 5 (1.5)        | 5 (5)       | 4 (2.3)                     | 1 (0.62)                | 0.21    |
| Language (%)             | 124 (37)       | 69 (68)    | 70 (40)                     | 54 (33)                 | 0.2     |
| Abstraction (%)          | 88 (26)        | 61 (60)    | 50 (29)                     | 38 (23)                 | 0.29    |
| Delayed recall (%)       | 237 (70)       | 94 (93)    | 121 (69)                    | 116 (72)                | 0.62    |
| Orientation (%)          | 7 (2)          | 6 (6)      | 7 (4)                       | 0 (0)                   | 0.01    |

P value for comparison of normal left ventricular function versus subclinical LVD. MoCA, Montreal cognitive assessment.

#### Table 3  Echocardiographic variables by presence or absence of mild cognitive impairment (MCI)

|                          | No MCI (n=236) | MCI (n=101) | P value |
|--------------------------|----------------|-------------|---------|
| LV ejection fraction, % (SD) | 62 (6.8)  | 62 (5.8) | 0.7     |
| GLS, % (IQR)             | 18.7 (17–20)  | 18.7 (17–20) | 0.87    |
| E/A ratio (IQR)          | 0.8 (0.68–0.95) | 0.82 (0.69–0.99) | 0.63    |
| e’, cm/s (IQR)           | 7.5 (6.3–8.9) | 7.5 (6.5–8.7) | 0.67    |
| E/e’ (IQR)               | 8.2 (6.9–10.2) | 8.7 (7.2–11) | 0.32    |
| LAVI, mL/m² (IQR)        | 34 (28–40)    | 33 (29–42) | 0.56    |
| LA reservoir strain*, % (SD) | 36.2 (7) | 36.1 (7) | 0.9     |
| LARS<24%* (%)            | 7 (4)         | 2 (3)       | 0.61    |
| Relative wall thickness (IQR) | 0.37 (0.34–0.43) | 0.39 (0.33–0.43) | 0.96    |
| LV mass indexed, g/m² (IQR) | 67 (55–79)  | 75 (60–84) | 0.04    |
| Subclinical LV dysfunction (%) | 113 (48) | 49 (48.5) | 0.9     |
| Systolic dysfunction (GLS≤16%) | 42 (18) | 13 (13) | 0.26    |
| Diastolic dysfunction (%) | 54 (23)       | 26 (26)    | 0.54    |
| LV hypertrophy (%)       | 13 (5.5)      | 7 (7)      | 0.62    |

*Available in 248 participants. GLS, global longitudinal strain; LARS, left atrial reservoir strain; LAVI, left atrial volume indexed to body surface area; LV, left ventricular.
## Table 4  Logistic regression modelling for prediction of mild cognitive impairment

|                        | Univariable |                      | Multivariable |                      |
|------------------------|-------------|----------------------|---------------|----------------------|
|                        | OR (95% CI) | P value              | OR (95% CI)   | P value              |
| Age, years             | 1.00 (0.95 to 1.06) | 0.88                  |               |                      |
| Female gender          | 0.8 (0.49 to 1.26)   | 0.32                  |               |                      |
| Hypertension           | 1.58 (0.75 to 3.33)  | 0.23                  |               |                      |
| Hypertension duration  | 1.00 (0.97 to 1.03)  | 0.76                  |               |                      |
| Type II diabetes       | 1.26 (0.77 to 2.06)  | 0.36                  |               |                      |
| Diabetes duration      | 1.03 (0.98 to 1.09)  | 0.22                  |               |                      |
| Dyslipidaemia          | 1.03 (0.63 to 1.66)  | 0.9                   |               |                      |
| Ever smoker            | 0.88 (0.23 to 3.44)  | 0.86                  |               |                      |
| Stroke/TIA             | 2.2 (0.87 to 5.6)    | 0.09                  | 2.5 (0.93 to 6.8)| 0.07                |
| AF (known)             | 1.54 (0.65 to 3.69)  | 0.33                  |               |                      |
| AF (detected or high risk) | 0.63 (0.2 to 1.96)   | 0.43                  |               |                      |
| Education, years       | 0.92 (0.86 to 0.98)  | 0.02                  | 0.9 (0.86 to 0.98)| 0.01                |
| Depression (PHQ-9>6), %| 0.8 (0.32 to 2)      | 0.6                   |               |                      |
| Anxiety (GAD-7>6), %   | 0.85 (0.33 to 2.1)   | 0.72                  |               |                      |
| ACE-I/ARB              | 1.17 (0.65 to 2)     | 0.59                  |               |                      |
| Beta blocker           | 1.7 (0.84 to 3.4)    | 0.14                  |               |                      |
| Statin                 | 1.14 (0.7 to 1.8)    | 0.58                  |               |                      |
| Antiplatelet           | 1.47 (0.84 to 2.59)  | 0.17                  |               |                      |
| Anticoagulant          | 1.43 (0.5 to 4)      | 0.5                   |               |                      |
| Systolic BP, mm Hg     | 1.02 (0.99 to 1.03)  | 0.07                  | 1.02 (1.00 to 1.04)| 0.03                |
| Diastolic BP, mm Hg    | 1.02 (0.99 to 1.04)  | 0.2                   |               |                      |
| BMI, kg/m²             | 0.93 (0.88 to 0.97)  | 0.001                 | 0.9 (0.85 to 0.95)| <0.001              |
| Waist–hip ratio        | 11 (0.8 to 161)      | 0.07                  | 40 (2.3 to 708) | 0.01                |
| NT-proBNP, pg/mL       | 0.99 (0.99 to 1.00)  | 0.7                   |               |                      |
| MVPA, hour/week        | 0.99 (0.99 to 1.00)  | 0.98                  |               |                      |
| Sedentary time, %      | 0.98 (0.94 to 1.01)  | 0.15                  |               |                      |
| Echocardiographic classifications |               |                      |               |                      |
| Subclinical LV dysfunction | 1.03 (0.64 to 1.63)  | 0.9                   |               |                      |
| Systolic dysfunction (GLS£16%) | 0.68 (0.35 to 1.33)  | 0.26                  |               |                      |
| Diastolic dysfunction  | 1.18 (0.69 to 2)     | 0.54                  |               |                      |
| LV hypertrophy         | 1.27 (0.49 to 3.3)   | 0.62                  |               |                      |
| Echocardiographic continuous measures |           |                      |               |                      |
| LV ejection fraction, %| 0.99 (0.95 to 1.03)  | 0.7                   |               |                      |
| GLS, %                 | 1.01 (0.92 to 1.11)  | 0.82                  |               |                      |
| e′, cm/s               | 0.96 (0.84 to 1.09)  | 0.57                  |               |                      |
| E/e′                   | 1.03 (0.94 to 1.12)  | 0.4                   |               |                      |
| LAVI mL/m²             | 1 (0.98 to 1.03)     | 0.56                  |               |                      |
| LA reservoir strain, % | 0.98 (0.96 to 1.04)  | 0.91                  |               |                      |
| LARS<24%               | 0.66 (0.13 to 3.27)  | 0.61                  |               |                      |
| LV mass indexed, g/m²  | 1.00 (0.99 to 1.02)  | 0.13                  |               |                      |

ACE-I/ARB, ACE inhibitor/angiotensin receptor blocker; AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; GAD-7, Generalized Anxiety Disorder 7-Item Scale; GLS, global longitudinal strain; LA, left atrial; LARS, left atrial reservoir strain; LAVI, left atrial volume indexed to body surface area; LV, left ventricular; MVPA, moderate-vigorous physical activity; NT-proBNP, N-terminal pro-brain natriuretic peptide; PHQ-9, Patient Health Questionnaire-9; TIA, transient ischaemic attack.
Symptomatic HF is independently associated CI, although data with robust adjustment for shared risk factors is sparse. Nevertheless, the impact is significant, with most recent estimates of incidence being around 30% over 3.5 years, with cerebral hypoperfusion and subclinical cardiogenic emboli likely mechanisms. Population studies demonstrate conflicting results regarding associations between LV function and cognition. Cross-sectional data from the Framingham Heart Study found a U-shaped relationship between LVEF quintiles and cognition with the extremes displaying worse cognitive performance (memory and executive function). Conversely, longitudinal data from the Netherlands demonstrated that LAVI but not LVEF at baseline was associated with lower performances in attention and executive function at follow-up. Furthermore, another cross-sectional population study found lower systolic function, assessed by tissue Doppler early systolic peak velocity, was not associated with poor cognitive performance but was associated with lower total brain volume. With regards LA size, several studies have demonstrated an association between greater LA size and CI by global assessment or specific domain testing. However, adjustment for AF is inconsistent and recent evidence suggests the association is not independent of AF.

Less is known about the link between cardiac dysfunction and cognition in asymptomatic patients. In patients with chronic heart disease (eg, coronary disease) but without symptomatic HF, diastolic filling pressure estimated by E/e’, was associated with significantly higher odds of MCI after comprehensive adjustment for clinical factors, although effect size was small (OR 1.07, 1.01–1.13, p=0.022). This finding did not extend to LVMI, LAVI or stroke volume index. In a population without symptomatic cardiac or cerebrovascular disease, those with SCIs on MRI had significantly lower systolic function, as assessed by GLS. Moreover, GLS in those with SCIs was in the abnormal range.

AF is associated with a 42% increase in risk of dementia, independent of age and cardiovascular risk factors. Interestingly, this association appears strongest in those <70 years with data suggesting no association >67 years, presumably due to the influence of neurodegenerative pathophysiology. This is significant given the median age in our study was 70 years. The most prominent mechanism behind the association between AF and CI is SCIs, the presence of which determine cognitive decline associated with AF, and conversely those with AF without SCIs do not exhibit cognitive decline. However, no study has examined the distribution of SCIs preventing inference about the pathophysiological mechanism, that is, small vessel vs embolic disease. Anticoagulation in AF is associated with up to a 60% reduction in cognitive decline and incident dementia, supporting a cardioembolic mechanism. Neuroimaging would have strengthened our study and revealed whether those with AF were free of SCIs thus potentially explaining the lack of association with MCI.

Clinical implications
Clinicians involved in management of patient with CV risk factors must be alert to the significant proportion of patients who will have MCI—affecting their ability to recall medical information and self-manage aspects of their condition. Indeed, those with MCI progress to dementia at a rate of over 50% in 5 years. Our data highlight that even in the early stages of cognitive compromise modifiable risk factors that is, systolic hypertension and abdominal obesity are contributors, and it may be argued that cognitive screening be undertaken routinely.
in this scenario. We did not find evidence of an association between certain echocardiographic measures, even sensitive markers of LV and LA function. So, based on these data, echocardiographic abnormality alone should not prompt cognitive evaluation.

In terms of HF prevention, while management of subclinical disease largely rests on risk factor control, the onus is on the patient to recognise the often-insidious transition to a symptomatic state. Current American College of Cardiology/American Heart Association HF management guidelines suggest that patients with subclinical HF undertake self-surveillance for symptoms and our data highlight one of the problems with this approach that is, the potential for under-recognition due to CI. While screening for subclinical LVD is not currently advocated, it is plausible that early institution of therapy may preserve cognition if progression to symptomatic HF is delayed or prevented. Indeed, anticoagulation for AF, whether permanent or paroxysmal, is associated with a significant reduction in CI, an observation that could extend to subclinical AF detected by screening.

One of the primary objectives of this study was to assess the prevalence of MCI and therefore the consequences to delivery of screening programmes for HF and AF. This study population may have been subject to selection bias given they had sufficient cognition to apply for the trial, meaning the true prevalence is likely higher. However, for those with established dementia, prevention of HF or AF is not their primary care goal. Population-based screening for dementia or MCI is not presently advocated, however, a novel proposal may be that HF/AF screening be used as a platform for cognitive screening given the high yield in this cohort. Our data suggest that strategies to optimise engagement and follow-up with an HF/AF screening programme should be considered. For example, engagement of services beyond the screening programme and consideration given to the impact of reduced cognition and health literacy. When cognition is compromised, close relatives can assist with health literacy to promote use of health services. Our finding of a 12% rate of non-adherence to self-initiated AF screening, that related to MCI, is also of importance in considering the mode of delivery of AF screening. Technologies like monitoring patches or smartwatches may be more effective than devices that participants are required to operate.

**Limitations**

The study would have been strengthened by a longitudinal design, to additionally assess impact on incident MCI. While our sample size was not based on calculation, it is comparable to other studies in specific populations. Furthermore, a larger sample size would have yielded more accurate effect sizes. As mentioned previously, brain MRI would have provided additional mechanistic insights. Our method of assessment for MCI was chosen both for its speed and validity. However, use of more detailed tests for individual cognitive domains may have added more depth to our results and made comparisons with other studies easier. Indeed, variation in the literature surrounding CV disease and cognition may be largely due to inconsistencies in methods. Finally, it should be borne in mind that while a significant proportion of subjects exhibited subclinical LVD, the number with reduced atrial function and/or subclinical AF was low, limiting the certainty of our observations.

**CONCLUSION**

Elderly subjects enrolled in a trial screening for subclinical LVD and AF exhibited a 30% prevalence of MCI. There was no association between sensitive measures of LV and LA function nor subclinical AF and presence of MCI.

---

**REFERENCES**

1. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. *JAM A* 2014;312:2551–61.
2. 2019 AloHaW. Hospital care for people with dementia 2016–17. cat no age 94. Canberra: AIHW.
3. Vogels RLC, Scheltens P, Schroeder-Tankja JM, et al. Cognitive impairment in heart failure: a systematic review of the literature. *Eur J Heart Fail* 2007;9:440–9.
4. Santangelo P, Di Biase L, Bai R, et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. *Heart Rhythm* 2012;9:1761–8.
5 Leto L, Feola M. Cognitive impairment in heart failure patients. J Geriatric Cardiol 2014;11:316–28.
6 Huynh QL, Negishi K, De Pasquale CG, et al. Cognitive domains and Postdischarge outcomes in hospitalized patients with heart failure. Circ Heart Fail 2019;12:e006086.
7 Almeida OP, Garrido GJ, Beer C, et al. Cognitive and brain changes associated with ischaemic heart disease and heart failure. Eur Heart J 2012;33:1769–76.
8 Frey A, Sell R, Homola GA, Homola György A, et al. Cognitive deficits and related brain lesions in patients with chronic heart failure. JACC Heart Fail 2018;6:583–92.
9 Sacre JW, Ball J, Wong C, et al. Mild cognitive impairment is associated with subclinical diastolic dysfunction in patients with chronic heart disease. Eur Heart J Cardiovasc Imaging 2018;19:285–92.
10 Russo C, Jin Z, Homma S, et al. Subclinical left ventricular dysfunction and silent cerebrovascular disease: the cardiovascular abnormalities and brain lesions (CABLI) study. Circulation 2013;128:1105–11.
11 Zhang MJ, Norby FL, Lutsey PL, et al. Association of left atrial enlargement and atrial fibrillation with cognitive function and decline: the ARIC-NCS. J Am Heart Assoc 2019;8:e013197.
12 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Ate statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7.
13. Available: https://www.mocatset.org
14 Abd Razak MA, Ahmad NA, Chan YY, et al. Validity of screening tools for dementia and mild cognitive impairment among the elderly in primary health care: a systematic review. Public Health 2019;169:84–92.
15 Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2015;28:1–39.
16 Nagues SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277–314.
17 Singh A, Addetta K, Maffessanti F, et al. LA strain for categorization of LV diastolic dysfunction. JACC Cardiovasc Imaging 2017;10:735–43.
18 Prins ND, van Dijk EJ, den Heijer T, et al. Association between left ventricular dysfunction and brain structure and function: findings from the sabre (Southall and Brent revisited) study. J Am Heart Assoc 2017;6:e004888.
19 Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004;61:1531–4.
20 de Bruijn RF, Heeringa J, Wolters FJ, et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol 2015;72:1288–94.
21 Marengoni A, Qiu C, Winblad B, et al. Atrial fibrillation, stroke and dementia in the very old: a population-based study. Neurobiol Aging 2011;32:1336–7.
22 Chen LY, Lopez FL, Gottesman RF, et al. Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the Atherosclerosis Risk in Communities study. Stroke 2014;45:2568–74.
23 Ding M, Fratiglioni L, Johrell K, et al. Atrial fibrillation, antithrombotic treatment, and cognitive aging: a population-based study. Neurology 2018;91:e1732–40.